Yahoo
    OTC Markets OTCQB - Delayed Quote USD

    Rhelion Life Sciences Corp. (TRUFF)

    Get top stock picks
    0.0249 +0.0019 (+8.26%)
    As of 9:35:22 AM EDT. Market Open.
    Get top stock picks
    Chart Range Bar
    Advanced Chart
    AlphaSpace Chart
    Loading chart for TRUFF
    • Previous Close 0.0230
    • Open 0.0250
    • Bid 0.0225 x 4903000
    • Ask 0.0250 x 4900000
    • Day's Range 0.0249 - 0.0250
    • 52 Week Range 0.0050 - 0.0430
    • Volume 1,046
    • Avg. Volume 193,671
    • Market Cap (intraday) 15.292M
    • Beta (5Y Monthly) --
    • PE Ratio (TTM) --
    • EPS (TTM) -0.0100
    • Earnings Date (est.) Nov 30, 2026
    • Forward Dividend & Yield --
    • Ex-Dividend Date --
    • 1y Target Est --

    Rhelion Life Sciences Corp. engages in the research and development of psychedelic drug in Netherlands, Canada, and the United States. Its products also include PEX010, a natural psilocybin drug candidate. It also engages in the production, growth, and sale of functional mushrooms and mushroom home grow kits to the recreational market in North America and Europe, as well as selection, distribution, and export of truffles. The company was formerly known as Red Light Holland Corp. and changed its name to Rhelion Life Sciences Corp. in August 2026. Rhelion Life Sciences Corp. is based in Toronto, Canada.

    www.rhelion.com

    --

    Full Time Employees

    March 31

    Fiscal Year Ends

    Healthcare

    Sector

    Drug Manufacturers - Specialty & Generic

    Industry

    More about Rhelion Life Sciences Corp.

    Recent News

    View More
    Rhelion Life Sciences Confirms Further Delivery of Filament Health's PEX010 to Germany's First Psilocybin Compassionate Use Program

    Rhelion Life Sciences Confirms Further Delivery of Filament Health's PEX010 to Germany's First Psilocybin Compassionate Use Program
    TMX Newsfile 3h ago
    Rhelion Life Sciences Reports First Quarter 2027 Results

    Rhelion Life Sciences Reports First Quarter 2027 Results
    TMX Newsfile 3d ago
    Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New United States Patent, Extending the Broadest Natural Psilocybin Patent Estate

    Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New United States Patent, Extending the Broadest Natural Psilocybin Patent Estate
    TMX Newsfile 7d ago
    Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 for University of Washington Phase 2a Trial in Cancer-Related Anxiety and Depression

    Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 for University of Washington Phase 2a Trial in Cancer-Related Anxiety and Depression
    TMX Newsfile 9d ago
    Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Letter of Intent with Darmiyan, Inc. to Explore Use of FDA De Novo Authorized BrainSee(R) AI Platform in Early Alzheimer's Disease Trial Design

    Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Letter of Intent with Darmiyan, Inc. to Explore Use of FDA De Novo Authorized BrainSee(R) AI Platform in Early Alzheimer's Disease Trial Design
    TMX Newsfile 14d ago
    Rhelion Life Sciences Announces Appointment of Samiuddin Khaja as CFO

    Rhelion Life Sciences Announces Appointment of Samiuddin Khaja as CFO
    TMX Newsfile 15d ago
    Rhelion Life Sciences Signs Agreement with University Health Network for Randomized Clinical Trial of Psilocybin in Parkinson's Disease Depression

    Rhelion Life Sciences Signs Agreement with University Health Network for Randomized Clinical Trial of Psilocybin in Parkinson's Disease Depression
    TMX Newsfile 20d ago

    Rhelion Life Sciences Corp. Commences Trading Under New Name and Ticker Symbol RHEL on the CSE
    TMX Newsfile 29d ago
    Red Light Holland Reports Fiscal 2026 Audited Year-End Results and Provides Update on Rhelion Life Sciences

    Red Light Holland Reports Fiscal 2026 Audited Year-End Results and Provides Update on Rhelion Life Sciences
    TMX Newsfile 1mo ago
    Red Light Holland Announces Corporate Rebrand to Rhelion Life Sciences Corp

    Red Light Holland Announces Corporate Rebrand to Rhelion Life Sciences Corp
    TMX Newsfile 1mo ago

    Red Light Holland Announces New Filament Health PEX010 European Research Shipment
    TMX Newsfile 1mo ago
    View More

    Performance Overview

    Trailing total returns as of 9/3/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

    YTD Return

    TRUFF
    46.47%
    S&P/TSX Composite index (^GSPTSE)
    14.33%

    1-Year Return

    TRUFF
    14.14%
    S&P/TSX Composite index (^GSPTSE)
    26.72%

    3-Year Return

    TRUFF
    56.32%
    S&P/TSX Composite index (^GSPTSE)
    77.33%

    5-Year Return

    TRUFF
    86.39%
    S&P/TSX Composite index (^GSPTSE)
    74.98%

    Earnings Trends

    View More

    Earnings Per Share

    Revenue vs. Earnings

    Annual
    Quarterly
    Annual
    Quarterly
    Q2 FY23
    Revenue 736.43k
    Earnings -1.26M
    Profit Margin -171.69%

    Q3

    FY22

    Q4

    FY22

    Q1

    FY23

    Q2

    FY23

    -6M
    -4M
    -2M
    0
    -1200.0%
    -1000.0%
    -800.0%
    -600.0%
    -400.0%
    -200.0%
    View More

    Statistics

    View More

    Valuation Measures

    Annual
    As of 9/1/2026

    • Market Cap

      13.30M

    • Enterprise Value

      7.79M

    • Trailing P/E

      --

    • Forward P/E

      --

    • PEG Ratio (5yr expected)

      --

    • Price/Sales (ttm)

      3.29

    • Price/Book (mrq)

      1.70

    • Enterprise Value/Revenue

      2.57

    • Enterprise Value/EBITDA

      --

    Financial Highlights

    Profitability and Income Statement

    • Profit Margin

      -181.28%

    • Return on Assets (ttm)

      -13.71%

    • Return on Equity (ttm)

      -41.31%

    • Revenue (ttm)

      3.83M

    • Net Income Avi to Common (ttm)

      -6.43M

    • Diluted EPS (ttm)

      -0.0100

    Balance Sheet and Cash Flow

    • Total Cash (mrq)

      3.11M

    • Total Debt/Equity (mrq)

      8.02%

    • Levered Free Cash Flow (ttm)

      -5.39M

    View More

    Compare

    Compare

    Select to analyze similar companies using key performance metrics; select up to 4 stocks.

    TRUFF
    Rhelion Life Sciences Corp.
    0.0249
    +8.26%
    Mkt Cap 15.292M
    Industry Drug Manufacturers—Specialty & Generic
    MEDXF
    Medexus Pharmaceuticals Inc.
    3.8180
    +3.19%
    Mkt Cap 119.984M
    Industry Drug Manufacturers—Specialty & Generic
    CXXIF
    C21 Investments Inc
    0.2647
    -0.11%
    Mkt Cap 31.414M
    Industry Drug Manufacturers—Specialty & Generic
    PHRX.CN
    Pharmadrug Inc.
    0.0050
    0.00%
    Mkt Cap CAD 671,071
    Industry Drug Manufacturers—Specialty & Generic
    RVVTF
    Revive Therapeutics Ltd.
    0.0180
    -5.26%
    Mkt Cap 7.842M
    Industry Drug Manufacturers—Specialty & Generic
    OVAT.CN
    Ovation Science Inc.
    0.0300
    0.00%
    Mkt Cap CAD 1.153M
    Industry Drug Manufacturers—Specialty & Generic
    CNGGF
    Cann Group Limited
    0.0034
    0.00%
    Mkt Cap 5.646M
    Industry Drug Manufacturers—Specialty & Generic
    MLLNF
    Malin Corporation plc
    6.40
    0.00%
    Mkt Cap 27.687M
    Industry Drug Manufacturers—Specialty & Generic
    JWCAF
    James E. Wagner Cultivation Corporation
    0.0001
    0.00%
    Mkt Cap 10,942
    Industry Drug Manufacturers—Specialty & Generic
    000989.SZ
    Jiuzhitang Co., Ltd.
    8.92
    -1.44%
    Mkt Cap CNY 7.635B
    Industry Drug Manufacturers—Specialty & Generic
    STMH
    Stem Holdings, Inc.
    0.0000
    0.00%
    Mkt Cap 66
    Industry Drug Manufacturers—Specialty & Generic

    People Also Watch

    MYCOF Noveris Health Sciences Inc.
    0.7300 0.00%
    RVVTF Revive Therapeutics Ltd.
    0.0180 -5.26%
    HAVLF HAVN Life Sciences Inc.
    0.0001 0.00%
    EHVVF EHAVE, Inc.
    0.0011 -35.29%
    HELP.NE Cybin D/B/A Helus Pharma
    15.76 -4.89%
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: